Trial Profile
A Randomized Multicenter, Double-Blind, Placebo-Controlled Comparison of Chemotherapy Plus Trastuzumab Plus Placebo Versus Chemotherapy Plus Trastuzumab Plus Pertuzumab as Adjuvant Therapy in Patients With Operable HER2-Positive Primary Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 12 Apr 2024
Price :
$35
*
At a glance
- Drugs Pertuzumab (Primary) ; Trastuzumab (Primary) ; Carboplatin; Cyclophosphamide; Docetaxel; Doxorubicin; Epirubicin; Fluorouracil; Paclitaxel
- Indications Carcinoma; Early breast cancer; HER2 positive breast cancer; Male breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms APHINITY
- Sponsors Roche
- 18 Mar 2024 Planned End Date changed from 30 Nov 2028 to 28 Nov 2024.
- 22 Nov 2023 This trial has been completed in Czechia, according to European Clinical Trials Database record.
- 20 Jul 2022 Results presented in a Chugai Pharmaceutical media release.